OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
54
Results
Show all
Save search
Copy query
Show results for
Unknown
(54)
Publication Date
Release Date
2022
(16)
2021
(14)
2024
(7)
2025
(4)
2023
(3)
2020
(2)
2019
(2)
2015
(2)
2011
(2)
2017
(1)
2016
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.
Not available
S-EPMC8117965
|
biostudies-literature
Cite
A plain language summary of how well the single-dose Janssen vaccine works and how safe it is.
Not available
S-EPMC8587777
|
biostudies-literature
Cite
A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.
Not available
S-EPMC5328205
|
biostudies-literature
Cite
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Not available
S-EPMC11125575
|
biostudies-literature
Cite
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
Not available
S-EPMC6548899
|
biostudies-literature
Cite
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Not available
S-EPMC9441209
|
biostudies-literature
Cite
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
Not available
S-EPMC8688528
|
biostudies-literature
Cite
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
Not available
S-EPMC9047246
|
biostudies-literature
Cite
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC10965106
|
biostudies-literature
Cite
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Not available
S-EPMC10632397
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets